Pamela Soliman
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.
Year:
2025
Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P P P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets ( CDK6 , GLS , MSLN , ERBB2 ), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.
Year:
2025
Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tumor cells interfaced with abundant CD8 T cells that demonstrated an exhausted state. This region was also enriched for interferon-stimulating signals. In contrast, region 2 represented tumor interior where very few CD8 T cells were observed. (B) Visium spatial profiling of the same sample as (A). CD8 T cell signals were detected in the tumor margin, which highly overlapped with the signals of immune checkpoint and interferon-stimulated genes.
Year:
2025
Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypoxia signaling highlighted. (B) GSEA showing enriched pathways in the tumor compartment of MRD samples.
Year:
2025
Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.
Year:
2025
PURPOSE Hypomagnesemia is a common side effect of platinum-based chemotherapy and predicts poor overall survival in some cancers. Standard magnesium replacement strategies are often inadequate for maintaining magnesium levels. We hypothesized that a daily dietary magnesium replacement approach through magnesium-rich foods would help maintain adequate magnesium levels during platinum-based treatment. MATERIALS AND METHODS We conducted a prospective feasibility study of magnesium-rich diets in patients 18 years and older with previously untreated ovarian cancer scheduled to receive carboplatin-containing chemotherapy of at least six consecutive cycles. Education about magnesium-rich diets was provided at enrollment and then weekly during chemotherapy. Feasibility was defined as ≥60% completion of dietary recalls and ≥280 mg average daily dietary magnesium intake across all patients. RESULTS Twenty-one of 26 patients enrolled completed at least five chemotherapy cycles and were included in the analysis. Adherence to the study diet was 76%. Daily dietary magnesium intake was 100.5 mg at baseline and increased throughout each cycle: 6% of patients at baseline, 24% after the first cycle, and 67% after the fifth cycle reached ≥280-mg/day magnesium intake. Seven (33%) of 21 had at least one incident of hypomagnesemia. Patients who were adherent had significantly lower incidence of hypomagnesemia (19% v 80%, P = .03) and less need for intravenous magnesium (6% v 60%, P = .03) than those who were nonadherent. CONCLUSION The study achieved primary feasibility objectives of retention and adherence to the study intervention. Weekly education about magnesium-rich diets was effective in increasing dietary magnesium intake. Adequate dietary magnesium appeared to be protective against hypomagnesemia.
Year:
2024
Year:
2024
Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular profiling data at our institution between February 2010 and August 2022 were included and grouped by RAS mutation status. Overall survival was estimated by the Kaplan–Meier method, and multivariable analysis was performed using the Cox proportional hazard model. Results: Of 3,328 gynecologic cancers, 523 (15.7%) showed any RAS mutation. Patients with RAS-mutated tumors were younger (57 vs. 60 years nonmutated), had a higher prevalence of endometriosis (27.3% vs. 16.9%), and lower grades (grade 1/2, 43.2% vs. 8.1%, all P KRAS mutation was in mesonephric-like endometrial (100%, n = 9/9), mesonephric-like ovarian (83.3%, n = 5/6), mucinous ovarian (60.4%), and low-grade serous ovarian (44.4%) cancers. After adjustment for age, cancer type, and grade, RAS mutation was associated with worse overall survival [hazard ratio (HR) = 1.3; P = 0.001]. Specific mutations were in KRAS (13.5%), NRAS (2.0%), and HRAS (0.51%), most commonly KRAS G12D (28.4%) and G12V (26.1%). Common co-mutations were PIK3CA (30.9%), PTEN (28.8%), ARID1A (28.0%), and TP53 (27.9%), of which 64.7% were actionable. RAS + MAPK pathway-targeted therapies were administered to 62 patients with RAS-mutated cancers. While overall survival was significantly higher with therapy [8.4 years [(95% confidence interval (CI), 5.5–12.0) vs. 5.5 years (95% CI, 4.6–6.6); HR = 0.67; P = 0.031], this effect did not persist in multivariable analysis. Conclusions: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA , PTEN , and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.
Year:
2024
Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.
Year:
2024
Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (36)
Richard Yang
Assistant Professor, Molecular Genetic Pathology
The University of Texas MD Anderson Cancer Center
Rossana Lazcano
The University of Texas MD Anderson Cancer Center
Christina Lynn Roland
The University of Texas MD Anderson Cancer Center
Jianjun Gao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Larissa A. Meyer
The University of Texas MD Anderson Cancer Center
Roni Wilke
The University of Texas MD Anderson Cancer Center
Yisheng LI
Professor
The University of Texas MD Anderson Cancer Center
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
Sanghoon Lee
Associate Professor
The University of Texas MD Anderson Cancer Center
Amir Jazaeri
Professor
The University of Texas MD Anderson Cancer Center
Shreyaskumar Patel
Professor
The University of Texas MD Anderson Cancer Center
David Gershenson
Professor
The University of Texas MD Anderson Cancer Center
Anthony P. Conley
Associate Professor
The University of Texas MD Anderson Cancer Center
Jeffrey How
Assistant Professor
The University of Texas MD Anderson Cancer Center
Meroe Morse
Assistant Professor
The University of Texas MD Anderson Cancer Center
Elizabeth Euscher
Professor
MD Anderson Cancer Center
Yibo Dai
The University of Texas MD Anderson Cancer Center
Shannon Westin
The University of Texas MD Anderson Cancer Center
Gwyn Richardson
Professor
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
J Andrew Livingston
Associate Professor
The University of Texas MD Anderson Cancer Center
Manoj Chelvanambi
The University of Texas MD Anderson Cancer Center
Gabriel Lopez
Associate Professor, Medical Director Integrative Medicine Center
The University of Texas MD Anderson Cancer Center
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
R. Tyler Hillman
Associate Professor
UC San Diego Health System
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Ying Yuan
Professor
The University of Texas MD Anderson Cancer Center
Kai Wucherpfennig
Professor and Department Chair
Dana-Farber Cancer Institute
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Wei-Lien Wang
Associate Professor
The University of Texas MD Anderson Cancer Center
Timothy Yap
The University of Texas MD Anderson Cancer Center
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
David Boruta
Professor
The University of Texas MD Anderson Cancer Center
Chia-Chin Wu
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.